BACK (IMAC Holdings) 5-Year EBITDA Growth Rate: 24.00% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is IMAC Holdings 5-Year EBITDA Growth Rate?

IMAC Holdings BACK -13.51% 5-Year EBITDA Growth Rate is 24.00% as of Sep. 2025. The stock has 7 warning signs investors should review.

IMAC Holdings's EBITDA per Share for the three months ended in Sep. 2025 was $-0.67.

During the past 3 years, the average EBITDA Per Share Growth Rate was 32.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 24.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of IMAC Holdings was 32.10% per year. The lowest was -119.60% per year. And the median was 9.05% per year.

IMAC Holdings  (OTCPK:BACK) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

IMAC Holdings 5-Year EBITDA Growth Rate Related Terms

BACK vs FCHS, NHLG, PAIYY: 5-Year EBITDA Growth Rate Comparison

For the Medical Care Facilities subindustry, IMAC Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IMAC Holdings 5-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, IMAC Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where IMAC Holdings's 5-Year EBITDA Growth Rate falls into.


IMAC Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 24.00% mean?
IMAC Holdings (BACK) has a 5-Year EBITDA Growth Rate of 24.00% as of Sep. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for IMAC Holdings and its competitors.
Is IMAC Holdings' 5-Year EBITDA Growth Rate too high?
IMAC Holdings' current 5-Year EBITDA Growth Rate is 24.00%.
How does IMAC Holdings' 5-Year EBITDA Growth Rate compare to FCHS and NHLG?
IMAC Holdings' 5-Year EBITDA Growth Rate of 24.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
A good 5-Year EBITDA Growth Rate depends on the Healthcare Providers & Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for IMAC Holdings and its competitors. IMAC Holdings's current 5-Year EBITDA Growth Rate is 24.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMAC Holdings stock overvalued right now?
IMAC Holdings (BACK) has a current 5-Year EBITDA Growth Rate of 24.00%. The current 5-Year EBITDA Growth Rate is 24.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For IMAC Holdings (BACK), the current 5-Year EBITDA Growth Rate is 24.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMAC Holdings Business Description

Address 3401 Mallory Lane, Suite 100, Franklin, TN, USA, 37067
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.